[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"healthy-aging\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:healthy-aging":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,71,0,25,[9,50,77,108,141,165,193,214,235,278,307,336,361,391,426,459,492,534,561,593,621,643,669,698,721],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100652533","peanut-butter-and-brain-health-100652533",false,"NCT07774546","Peanut Butter and Brain Health","Long-term Peanut Butter Consumption and Brain Health in Humans","Inclusion Criteria:\n\n* Men and women, aged between 45-75 years\n* Women postmenopausal: two or more years after last menstruation\n* Fasting plasma glucose \\\u003C 7.0 mmol\u002FL\n* Fasting serum total cholesterol \\\u003C 8.0 mmol\u002FL\n* Fasting serum triacylglycerol \\\u003C 4.5 mmol\u002FL\n* Systolic blood pressure \\\u003C 160 mmHg and diastolic blood pressure \\\u003C 100 mmHg\n* Stable body weight (weight gain or loss \\\u003C 3 kg in the past three months)\n* Willingness to give up being a blood donor from 8 weeks before the start of the study, during the study and for 4 weeks\n* after completion of the study\n* No difficult venipuncture as evidenced during the screening visit\n\nExclusion Criteria:\n\n* Allergy or intolerance to peanuts\n* Left-handedness (effects on brain health differ between left- and right-handed adults)\n* Current smoker, or smoking cessation \\\u003C 12 months\n* Diabetic patients\n* Familial hypercholesterolemia\n* Abuse of drugs\n* More than 3 alcoholic consumptions per day\n* Use of products or dietary supplements known to interfere with the main outcomes as judged by the principal investigators\n* Use of medication to treat blood pressure, lipid, or glucose metabolism\n* Use of an investigational product within another biomedical intervention trial within the previous 1-month\n* Severe medical conditions that might interfere with the study, such as epilepsy, asthma, kidney failure or renal insufficiency, chronic obstructive pulmonary disease, inflammatory bowel diseases, auto inflammatory diseases, and rheumatoid arthritis\n* Active cardiovascular disease like congestive heart failure or cardiovascular event, such as an acute myocardial infarction or cerebrovascular accident\n* Contra-indications for MRI imaging (e.g., pacemaker, surgical clips\u002Fmaterial in body, metal splinter in eye, claustrophobia)",true,"ALL","45 Years","75 Years",{"count":22,"type":23},45,"ESTIMATED","INTERVENTIONAL",[26],"NA","Healthy foods, including peanuts, may improve brain function, which is essential for cognitive and metabolic health, and may contribute to improved food intake regulation. It is therefore important to investigate the specific effects of peanut butter on cerebral blood flow responses, as well as the potential associated functional benefits. The researchers hypothesize that long-term peanut butter consumption improves vascular function in the brain, thereby enhancing cognitive performance and appetite control in middle aged and older adults. Objective: The primary objectives are to investigate in middle aged and older men and women the effect of 16-week peanut butter consumption on brain vascular function, while we will also assess changes in cognitive performance and appetite-related brain reward activity (secondary objectives). Cerebral blood flow responses (brain vascular function) will be non-invasively quantified by the non-invasive gold standard magnetic resonance imaging (MRI)-perfusion method Arterial Spin Labeling (ASL).Study design: This intervention study will have a randomized, controlled, cross-over design. The total study duration will be 40 weeks, including two 16-week interventions, separated by a washout period of at least 8 weeks. Study population: Forty-five middle-aged and older men and women (aged 45-75 years) without a history of cardiovascular diseases or complaints will participate. This population is expected to have a decreased cerebral blood flow at baseline and are also at increased risk of cognitive impairment, allowing for improvement by the intervention. Intervention: Study participants will receive, in random order, 45 g of peanut butter daily (peanut intervention) or no peanut butter (control) for a total of 16 weeks, separated by a wash-out period of at least 8 weeks. Main study parameters\u002Fendpoints: At baseline, first anthropometric measurements will be performed and blood pressure will be determined. In addition, a fasting blood sample will be drawn. Another fasting blood sample will be drawn at eight weeks, while participants have to attend the research facilities to perform follow-up measurements after sixteen weeks. The primary endpoint is the difference at follow-up in the cerebral blood flow response between peanut butter intervention and control periods. Cognitive performance will be assessed, while the researchers will also focus on appetite-related brain reward activity (secondary outcomes).",[29,30],"Healthy Aging","Middle-aged and Older Adults",[32,33,34,35,36],"Peanuts","Peanut butter","Brain","Cognitive health","Metabolic health","NOT_YET_RECRUITING","2026-08-17",{"date":40,"type":41},"2026-08-19","ACTUAL",{"date":43,"type":23},"2026-09",{"date":45,"type":23},"2028-07",{"name":47,"class":48},"Penn State University","OTHER",1,{"id":51,"slug":52,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":17,"sex":18,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":24,"phases":61,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":72,"completionDateStruct":73,"leadSponsor":75,"locationsCount":49},"100649632","sandplay-act-older-structured-sandplay-activity-for-older-individuals-100649632","NCT07735351","Sandplay-Act. Older: Structured Sandplay Activity for Older Individuals","The Effect of Structured Sandplay Activities on Positive and Negative Affect and Meaning in Life in Older Individuals: A Randomized Controlled Study","Inclusion Criteria:\n\n* Voluntary participation in the study\n* No specific condition that would cause learning difficulties (auditory or visual perception disorders, etc.)\n* Being between 65-80 years of age\n* No acute psychiatric disorder or severe cognitive impairment\n\nExclusion Criteria:\n\n* Having a mental or physical disability that prevents communication and attendance at sessions (inability to speak, diagnosis of severe dementia, etc.)","65 Years","80 Years",{"count":60,"type":23},60,[26],"This research was planned to determine the effect of structured sandplay activities on positive and negative affect and levels of meaning in life in elderly individuals. The research will be conducted as a single-blind, randomized controlled trial with a pre-test, post-test design at the Gül Kokulu Çınarlar Vefa Konağı of the Isparta Municipality Health Affairs Directorate between July 2026 and July 2027. Prior to the research, ethical committee approval and institutional permission for implementation will be obtained. The research population consists of 400 individuals registered with the institution. The sample will consist of 60 individuals (30 in the intervention group and 30 in the control group) who meet the inclusion criteria, are selected using block randomization, and provide informed consent. The control group will receive no intervention; a pre-test will be administered on the first day, and a post-test will be administered on the day the intervention for the experimental group ends. The intervention group will participate in sandplay activities twice a week for a total of four sessions; a pre-test will be administered on the first day, and a post-test will be administered in the last session. Data collection is planned for the period between July 2026 and July 2027 using the Personal Information Form (PIF), the Positive-Negative Affect Scale (PANAS), and the Meaning in Life Scale (MLS). Data will be analyzed using the SPSS (Statistical Program for Social Sciences) statistical analysis package, and statistical significance will be accepted at p \\\u003C 0.05.",[29,64],"Elderly (People Aged 65 or More)",[66,67,68,69],"elderly","positive and negative emotions","meaning in life","sandplay","2026-08-15",{"date":40,"type":41},{"date":38,"type":23},{"date":74,"type":23},"2027-03-31",{"name":76,"class":48},"Suleyman Demirel University",{"id":78,"slug":79,"hasResults":12,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":17,"sex":18,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":24,"phases":88,"briefSummary":89,"conditions":90,"keywords":94,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":49},"100648901","cardiorespiratory-fitness-and-acute-high-intensity-exercise-effects-on-brain-and-cognitive-function-in-older-adults-100648901","NCT07727577","Cardiorespiratory Fitness and Acute High-Intensity Exercise Effects on Brain and Cognitive Function in Older Adults","ExBrain","Inclusion Criteria:\n\n* Physical active in the last three months (\\>3x\u002Fweek of 30 minutes of moderate exercise)\n* To participate in the study, participants must answer \"no\" to all the Physical Activity Readiness questionnaire (PAR-Q) questions and have no signs and symptoms of cardiovascular, metabolic, and kidney diseases following the decision tree of the American College of Sports Medicine screening procedure.\n* Agree to have their data stored in a human performance database for future use. Agree to have their data stored in a repository per the requirement of peer-reviewed scientific journals, which may require data to be stored in a repository as a condition for publication. Such repositories are online databases, in which coded data is linked (no link to participants personally) to the journal article citation. Must read, understand, and sign the informed consent form.\n\nExclusion Criteria:\n\n* Use of illicit drugs, excessive alcohol, and\u002For performance-enhancing drugs.\n* Have any current orthopedic injury.\n* Have implanted medical devices.\n* Serious medical conditions limiting the ability to safety participate in either the PA interventions; these include dementia, symptomatic heart or vascular disease, severe hypertension, recent myocardial infarction, stroke, severe insulin-dependent diabetes mellitus, psychiatric disease, renal disease, liver disease or active cancer\n* Mini-mental examination score \\\u003C 23","55 Years","79 Years",{"count":87,"type":23},50,[26],"The goal of this clinical trial is to learn whether a single session of high-intensity interval exercise (HIIT) affects cognitive performance and brain activity in older adults, and whether cardiorespiratory fitness influences these effects. The main questions it aims to answer are:\n\n* Does a single HIIT session change performance on a task-switching test of cognitive flexibility?\n* Does a single HIIT session change prefrontal brain activity during cognitive testing, as measured by functional near-infrared spectroscopy (fNIRS)?\n* Do older adults with higher cardiorespiratory fitness show greater cognitive and brain changes in response to HIIT than those with lower fitness?\n\nParticipants will:\n\n* Visit the laboratory on two separate days\n* Complete a sub-maximal graded exercise test during the first visit to measure cardiorespiratory fitness\n* Complete a single \\~30-minute HIIT cycling session during the second visit\n* Complete a task-switching cognitive test before and after the HIIT session\n* Have their brain activity monitored with fNIRS while completing the cognitive tests",[29,91,92,93],"Cognitive Benefits","Cardio Respiratory Fitness","Brain Activity",[95,96,97,98],"Cognitive Flexibility","Prefrontal Cortex Activation","Aging","Acute effects of high-intensity interval exercise on cognitive flexibility and prefrontal brain activity in healthy older adults","2026-08-11",{"date":101,"type":41},"2026-08-12",{"date":103,"type":23},"2026-09-01",{"date":105,"type":23},"2028-08-01",{"name":107,"class":48},"Colby-Sawyer College",{"id":109,"slug":110,"hasResults":12,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":17,"sex":18,"minAge":115,"maxAge":20,"enrollmentInfo":116,"targetDuration":4,"studyType":24,"phases":117,"briefSummary":118,"conditions":119,"keywords":124,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":49},"100651481","the-effects-of-quercefit-and-ubiqsome-in-mitigating-inflammation-and-promoting-metabolic-health-100651481","NCT07760506","The Effects of Quercefit® and Ubiqsome™ in Mitigating Inflammation and Promoting Metabolic Health","The Effects of Quercefit® and Ubiqsome™ in Mitigating Inflammation and Promoting Metabolic Health - A Randomized, Double-Blind, Placebo-Controlled Study","Inclusion Criteria:\n\n* Males and females aged 50 to 75 years\n* Participants who meet the requirements of a sedentary lifestyle. Meaning, subjects who do not meet the World Health Organization's (WHO) minimum activity guidelines, of at least 150 minutes of moderate-intensity activity, or, 75 minutes of vigorous-intensity activity a week, plus muscle-strengthening activities at least 2 days per week. Of importance, incidental physical activity (eg, walking to work, household activities) would not meet the standard of being physically active according to WHO guidelines (McKay et al., 2021).\n* BMI of \\> or equal to 25.00kg\u002Fm²\n* Individuals with \\> or equal to 5 score relative to high risk for prediabetes as defined by the CDC (https:\u002F\u002Fwww.cdc.gov\u002Fprediabetes\u002Ftakethetest)\n* Free of all other chronic diseases.\n* Not currently using glucose-lowering agents or insulin.\n* Able to read and write in English\n* Willing to maintain a habitual diet, supplement routine, and avoid other lifestyle changes during the study period.\n* During the study, participants agree not to take any other supplement that can impact glucose or insulin regulation.\n* During the study, participants agree not to take any other supplement that can impact cardiovascular health, inflammatory status, or anti-aging supplements\n* Willing to have blood drawn\n* Must have access to a reliable internet connection and a computer to complete remote assessments\n\nExclusion Criteria:\n\n* Unwilling to have blood drawn\n* Unwilling to swallow pills\n* Pregnancy or has breast fed within 3 months prior to enrollment\n* Current use of prescription medication or drug that impacts Glucose or Insulin metabolism (including direct insulin treatment) within the past 6-months\n* Current use of Quercetine or CoQ10 supplements within the past 4-weeks\n* History or current alcohol or drug abuse\n* Known diagnosis of any chronic cardiovascular, metabolic, endocrine, or renal disease outside of prediabetes as listed above.\n* Has significant concurrent illnesses (controlled or uncontrolled), such as lupus, hepatitis B\u002FC, HIV, serious mental health illness such as dementia or schizophrenia; psychiatric hospitalization in the past two years, or other conditions, which in the opinion of the investigator, such condition might be aggravated as a result of treatment\n* Developmental disability or cognitive impairment that would preclude adequate comprehension of the informed consent form and\u002For ability to follow study subject requirements and\u002For record the necessary study measurements.\n* History of cardiovascular disease (i.e., myocardial infarction, hypertension, hypercholesterolemia, peripheral vascular disease, other)\n* History of neurological disorders (Parkinson's, Amyotrophic lateral sclerosis, epilepsy, spinal cord injury resulting in inability to use upper extremities, other.)\n* History of gastrointestinal disorders that could lead to uncertain absorption of the study supplements (i.e., inflammatory bowel disease, ulcerative colitis, -Crohn's disease, colostomy, or eating disorder)\n* History of kidney or liver disease\n* History of metabolic disorders (diabetes, metabolic syndrome, other)\n* History of current malignancy\u002Fcancer\n* Receiving chemotherapy agents or radiation treatments\n* Diagnosis of a terminal illness\n* The investigator feels that, for any reason, the subject is not eligible to participate in the study","50 Years",{"count":60,"type":23},[26],"The goal of this clinical trial is to learn if Quercefit® or Ubiqsome™ can improve markers of healthy aging, blood sugar control, and heart health in older adults. It will also learn about the safety of these supplements.\n\nThe main questions it aims to answer are:\n\n1. Do Quercefit® or Ubiqsome™ improve blood sugar, cholesterol, and markers of aging compared to a placebo?\n2. What side effects, if any, do participants have while taking these supplements?\n\nResearchers will compare Quercefit® (500 mg\u002Fday), Ubiqsome™ (300 mg\u002Fday), and a placebo (a look-alike capsule with no active ingredient).\n\nParticipants will:\n\n1. Take their assigned capsules (Quercefit®, Ubiqsome™, or placebo) twice daily for 12 weeks\n2. Go to a preferred clinic at the start and end of the study for a fasting blood draw\n\n   Complete at-home tests:\n3. Grip strength testing (using a device mailed to them)\n4. Online surveys about fatigue and quality of life\n5. Report any side effects and keep track of supplement use",[29,120,121,122,123],"Inflammaging","Metabolic Health","Quercetin","Coenzyme Q10",[29,120,121,125,126,127,128,129,130,131],"Blood testing","Pre-Diabetic","Composite Inflammaging Metric","Blood Glucose Regulation","Neuromuscular Function","Fatigue Impact Scale","Quality of life","2026-08-10",{"date":101,"type":41},{"date":135,"type":23},"2026-08",{"date":137,"type":23},"2028-08",{"name":139,"class":140},"Applied Science & Performance Institute","INDUSTRY",{"id":142,"slug":143,"hasResults":12,"nctId":144,"briefTitle":145,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":17,"sex":18,"minAge":115,"maxAge":20,"enrollmentInfo":147,"targetDuration":4,"studyType":24,"phases":149,"briefSummary":150,"conditions":151,"keywords":153,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":158,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":49},"100599091","effects-of-freeze-dried-grape-powder-on-immune-profiles-in-healthy-aging-adults-100599091","NCT07079982","Effects of Freeze-dried Grape Powder on Immune Profiles in Healthy Aging Adults","Inclusion Criteria:\n\n* 50-75 years old (at time of screening)\n* Body mass index (BMI) 18.5 to \\\u003C 30 kg\u002Fm2\n* Willing to consume grape and control powder during study periods, and refrain from eating grapes and certain other polyphenol-rich foods and beverages during the study\n* Do not fit any exclusion criteria\n\nExclusion Criteria:\n\n* \\\u003C50 years old and \\>75 years old\n* BMI \\\u003C18.5 and ≥ 30 kg\u002Fm2 or body weight \\\u003C 110 pounds\n* Experienced \\>10% weight change in the past 4 weeks\n* Elevated fasting glucose levels (fasting glucose higher than 126 mg\u002FdL) and triglycerides greater than 500 mg\u002FdL\n* Self-reported and\u002For physician-diagnosed history of diabetes mellitus, coronary heart disease, stroke, renal or liver disease, cancer, eating disorders, certain severe and\u002For relapsing\u002Fremitting autoimmune, inflammatory, or metabolic diseases, chronic infections, scleroderma, blood clotting disorders, intravenous drug use, or current pregnancy or lactation\n* Allergy to grapes or any ingredients in the grape or control powders\n* Implanted medical device (e.g., pacemaker) or other health condition that would prevent measurement of body composition by bioelectrical impedance\n* Currently taking lipid-lowering medications (e.g., statins, fibrates), glucose-regulating medications, anti-inflammatory medications (e.g., non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids), or medications that primarily affect blood clotting (e.g., warfarin), long-term antibiotics in the last 3 months, active use of probiotics during the intervention\n* Active smoker",{"count":148,"type":23},28,[26],"The purpose of this study is to investigate the effects of consuming grape powder on immune profiles in healthy middle- and older-aged individuals. Specifically, the investigators are interested in evaluating the potential effects of grapes in influencing markers of immune function, inflammation, and metabolism that are known to change with aging. Grapes contain several nutrients and antioxidant polyphenols such as resveratrol, quercetin, vitamin K and fiber, which are known to promote heart and immune health. However, the effects of grapes on altering immune profiles within the context of aging is not well understood. Therefore, this study will explore how daily grape consumption impacts certain markers of immunity in healthy middle- and older-aged adults.\n\nThe main study procedures include consumption of a freeze-dried grape powder and control powder (which tastes the same but has none of the grape compounds that are being studied) mixed with water as a beverage on a daily basis for 4 weeks each. The investigators will additionally ask that participants avoid eating grapes and certain other antioxidant\u002Fgrape-related foods and beverages throughout the 13-week study. Participants will additionally be asked to complete surveys about their diet, physical activity, and medical history, as well as provide blood samples and body weight measures throughout the course of the study. Participation in the study is expected to last about 6.25 hours over the course of 13 weeks and will include 7 visits.",[29,152],"Inflammation",[154,155,152,156],"Grapes","Healthy aging","Immune profiles","RECRUITING",{"date":101,"type":41},{"date":160,"type":41},"2025-07-25",{"date":162,"type":23},"2027-09",{"name":164,"class":48},"University of Connecticut",{"id":166,"slug":167,"hasResults":12,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":17,"sex":18,"minAge":172,"maxAge":58,"enrollmentInfo":173,"targetDuration":4,"studyType":24,"phases":175,"briefSummary":176,"conditions":177,"keywords":178,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":49},"100598349","neuroathletic-exercise-in-the-elderly-100598349","NCT07070336","Neuroathletic Exercise In The Elderly","The Effect Of Neuroathletic Exercise On Walking Speed, Fall Risk And Cognitive Functions In The Elderly","Inclusion Criteria:\n\n* Ages between 60-80\n* Volunteering to participate in the study\n* Having the ability to perform physical, cognitive and sensory tests and exercises\n\nExclusion Criteria:\n\n* Having a history of injury to the lower and upper extremities within the last year\n* Having regular physical activity or sports habits.\n* Having participated in any physical activity program in the last 6 months\n* Having a sensory pathology that prevents participation in the study\n* Having any musculoskeletal, neurological, respiratory or cardiovascular pathology that will limit exercise\n* Having a history of malignant disease\n* Having an eye defect that cannot be corrected with lenses, such as cataracts, that prevents tests","60 Years",{"count":174,"type":23},40,[26],"Objective: The aim of this protocol study was to investigate the effect of neuroathletic exercise on walking speed, fall risk and cognitive function in the elderly.\n\nMethod: The study is planned as a single-centre, double-blind, parallel group randomised controlled experimental design and will be conducted in accordance with SPIRIT. The sample of the study will consist of healthy elderly people aged 60-80 years. In order to ensure parametric conditions, the sample will be divided into two groups as experimental group (n=20) in which neuroathletic exercise will be performed and control group (n=20) in which Turkey Physical Activity Guidelines will be given and a total of 40 elderly people will be randomly assigned to the groups. The elderly assigned to the experimental and control groups according to the order of randomisation will be administered the timed up and go test (TUG), short physical performance battery (SPPB), geriatric depression scale (GDÖ), MoCA test as pre-test and post-test. The experimental group will be asked to perform neuroathletic exercises two days a week for 12 weeks under the supervision of a physiotherapist, and will be asked to perform a home exercise programme one day a week. The control group will be given the Turkish Physical Activity guide. Data will be collected by the researcher.\n\nResults: Considering the limited number of studies on the use of neuroathletic exercises in the literature, it is thought that our randomised controlled study designed to determine the effect of neuroathletic exercise on walking speed, fall risk and cognitive functions in the elderly will contribute to the literature.",[29],[179,180,181,182,183,184],"aging","neuroathletic exercise","walking speed","gait speed","fall risk","cognitive function","2026-08-06",{"date":132,"type":41},{"date":188,"type":41},"2025-05-01",{"date":190,"type":23},"2026-12-01",{"name":192,"class":48},"KTO Karatay University",{"id":194,"slug":195,"hasResults":12,"nctId":196,"briefTitle":197,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":17,"sex":18,"minAge":172,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":24,"phases":202,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":49},"100636944","adjuvant-nitrate-to-boost-exercise-induced-health-benefits-in-older-adults-100636944","NCT07572266","Adjuvant Nitrate to Boost Exercise-induced Health Benefits in Older Adults","BOOST-X","Inclusion Criteria:\n\n1. Male or female aged 60 years or older\n2. Free of chronic disease or disorder that would preclude full participation or have the potential to confound results\n3. No structured exercise program (2 or more bouts\u002Fwk) within previous 12 months\n4. Cognitively capable of providing informed consent\n\nExclusion Criteria:\n\n1. BMI ≥ 30.0 kg\u002Fm2\n2. Neurodegenerative disease\n3. Neuromuscular, musculoskeletal or orthopedic disorder or condition that would limit ability to perform the exercise prescription and\u002For physical performance testing\n4. Diagnosed orthostatic hypotension, i.e., a drop in systolic blood pressure of at least 20 mmHg or a drop in diastolic blood pressure of at least 10 mmHg within three minutes of standing up from a sitting or lying position.\n5. Resting blood pressure \\\u003C90\u002F60 mmHg or \\>160\u002F95 mmHg\n6. Uncontrolled hypertension\n7. Any current cardiovascular disease or cardiopulmonary instability\n8. Recent cardiovascular event or procedure within the preceding 6 months\n\n   1. If valve replacement has been performed, patient may not be enrolled for 12 months after the procedure\n   2. Any mechanical valve replacement that requires continuous warfarin anti-coagulation\n9. Anemia: Hgb \\\u003C11.0 (♂),10.0 (♂) gm\u002Fdl\n10. Diabetes with HgbA1c \\>7.0% or fasting blood glucose ≥ 130 mg\u002Fdl\n11. Liver disease with ALT \\> 52 U\u002Fl)\n12. Chronic kidney disease (eGFR \\\u003C 45)\n13. Any current infectious disease\n14. Any other disease or disorder that could influence exercise response, preclude full participation or have the potential to confound results (e.g., chronic lung disease, cognitive impairment, current cancer diagnosis or within 2 yr remission, cerebrovascular disease, pain)\n15. Life expectancy \\\u003C 1 year Medications \u002F lifestyle\n16. Insulin sensitizing\u002Fblood glucose lowering agents such as metformin\n17. Currently on or have used GLP-1 agonist or other metabolic \u002F weight loss drug in previous 12 weeks\n18. Use of nitrate medications\n19. High dose statin (≥40 mg\u002Fd simvastatin equivalence)\n20. Chronic corticosteroids\n21. Testosterone or other anabolic\u002Fandrogenic hormone therapy\n22. Lidocaine allergy\n23. Regular tobacco use and\u002For vaping \\> 1\u002Fwk\n24. Use of cannabis \\> 1\u002Fwk\n25. Excessive alcohol consumption (3 drinks\u002Fd or 7 drinks\u002Fwk for females; 4 drinks\u002Fd or 14 drinks\u002Fwk for males)\n26. Use of illicit drugs (e.g., cocaine, opioids)\n27. Unable to commit to \\~4 months required to complete the study",{"count":201,"type":23},226,[26],"Aging-related functional declines are thought to be caused by hallmark biological processes that ultimately manifest in physical, mental, and metabolic impairments to compromise intrinsic capacity and healthspan. Exercise is the only multipotent treatment with promise to mitigate many of the aging hallmarks, but there is substantial variability in individual exercise responsiveness. Thus, the investigators approach to boosting exercise responsiveness in aging is to combine an exercise training prescription containing both endurance and resistance training (in alignment with DHHS guidelines) with a nitrate-enriched dietary supplement to augment the cellular, tissue, and systemic adaptations that induce myriad health benefits of exercise in older adults.",[97,205,29],"Aging Well","2026-08-05",{"date":132,"type":41},{"date":209,"type":23},"2026-11",{"date":211,"type":23},"2031-05",{"name":213,"class":48},"Florida Institute for Human and Machine Cognition",{"id":215,"slug":216,"hasResults":12,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":17,"sex":18,"minAge":221,"maxAge":84,"enrollmentInfo":222,"targetDuration":4,"studyType":24,"phases":223,"briefSummary":224,"conditions":225,"keywords":4,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":230,"completionDateStruct":231,"leadSponsor":233,"locationsCount":49},"100650679","nvtia-ergothioneine-for-healthy-aging-and-skin-health-100650679","NCT07750002","NVTIA® Ergothioneine for Healthy Aging and Skin Health","A Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Effects of NVTIA® Ergothioneine Supplementation on Healthy Aging Biomarkers and Skin Health in Healthy Adults","Inclusion Criteria:\n\n* Participants must meet all of the following criteria:\n\n  * Male or female adults aged 35 to 55 years.\n  * Generally healthy as determined by medical history, physical examination, and screening assessments.\n  * Body Mass Index (BMI) between 18.5 and 29.9 kg\u002Fm².\n  * Willing and able to provide written informed consent.\n  * Willing to maintain their usual diet, physical activity, and lifestyle throughout the study period.\n  * Willing to avoid the use of other antioxidant, anti-aging, or nutritional supplements during the study period unless approved by the investigator.\n  * Able and willing to comply with all study procedures and scheduled visits.\n\nExclusion Criteria:\n\n* Participants meeting any of the following criteria will be excluded:\n\n  * History of clinically significant cardiovascular, hepatic, renal, gastrointestinal, endocrine, neurological, or psychiatric disease.\n  * Current diagnosis of diabetes mellitus requiring medication.\n  * Active inflammatory or autoimmune disease.\n  * History of malignant disease within the previous five years.\n  * Pregnancy, breastfeeding, or planning pregnancy during the study period.\n  * Known allergy or hypersensitivity to ergothioneine or any ingredient of the study product.\n  * Use of antioxidant supplements, anti-aging supplements, or investigational products within 30 days before enrollment.\n  * Current smoker or history of heavy alcohol consumption.\n  * Participation in another clinical trial within the previous 30 days.\n  * Any medical condition or laboratory abnormality that, in the opinion of the investigator, may interfere with study participation or interpretation of study results.","35 Years",{"count":87,"type":23},[26],"This study is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effects of NVTIA® Ergothioneine, a branded ergothioneine ingredient, on healthy aging biomarkers and skin health in healthy adults aged 40 to 65 years. Participants will receive either NVTIA® Ergothioneine or a matching placebo once daily for 12 weeks.\n\nThe primary objective of this study is to evaluate the effects of NVTIA® Ergothioneine supplementation on biomarkers associated with oxidative stress and healthy aging. Secondary objectives include assessment of skin elasticity, skin hydration, inflammatory biomarkers, and overall safety. The findings of this study are expected to provide clinical evidence supporting the role of NVTIA® Ergothioneine in promoting healthy aging and maintaining skin health.",[29,226,227],"Skin Aging","Oxidative Stress","2026-08-03",{"date":185,"type":41},{"date":70,"type":23},{"date":232,"type":23},"2027-04-08",{"name":234,"class":48},"EUROPEAN LIFE SCIENCE RESEARCH ASSOCIATION",{"id":236,"slug":237,"hasResults":12,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":4,"eligibilityCriteria":241,"healthyVolunteers":17,"sex":18,"minAge":172,"maxAge":4,"enrollmentInfo":242,"targetDuration":4,"studyType":244,"phases":4,"briefSummary":245,"conditions":246,"keywords":249,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":274,"leadSponsor":276,"locationsCount":4},"100649349","cmind-ai-web-tool-usability-study-hong-kong-100649349","NCT07735013","cMIND AI Web Tool Usability Study (Hong Kong)","Development and Validation of a Web-Based AI System for Assessing the Cantonese-Style Mediterranean Diet (cMIND) Index","Inclusion Criteria:\n\n* Aged 60 years or above\n* Community-dwelling in Hong Kong\n* Able to provide informed consent\n* Basic ability to use a smartphone or tablet (with assistance if needed)\n* Consuming Cantonese-style meals as the primary dietary pattern for ≥ 5 days per week for the past 3 months or longer)\n\nExclusion Criteria:\n\n* Severe visual or motor impairment that prevents taking meal photos even with assistance\n* Self-reported diagnosis of dementia or Alzheimer's disease, or other psychiatric\u002Fmedical conditions that would interfere with participation or valid outcome assessment\n* Current participation in other interventional nutrition or technology studies",{"count":243,"type":23},20,"OBSERVATIONAL","This study is testing a new web-based tool that uses artificial intelligence (AI) to help older adults in Hong Kong check how healthy their Cantonese-style meals are for brain health. The tool is based on the cMIND diet, a Chinese-adapted version of a known healthy eating pattern that may support memory and thinking skills.\n\nParticipants will use the web app to take photos of their usual meals for at least 10 days over two weeks. The AI will automatically identify ingredients and give a score showing how well the meal follows the cMIND diet. The study will also ask participants to complete a short questionnaire and a brief interview to find out how easy and useful the tool is for older adults.\n\nThe purpose of this small study is to see whether the AI tool is user-friendly and acceptable for older people. Results will help improve the tool for future use to support healthy ageing and brain health.",[247,29,248],"Mild Cognitive Impairment (MCI)","Nutrition",[250,251,252,253,254,255,256,257,258,259,260,261,262,263,264,265,266,267,268,269],"cMIND diet","Cantonese Mediterranean diet","AI dietary assessment","web-based AI tool","meal photo analysis","Cantonese mixed dishes","usability testing","older adults","congitive health","mild cognitive impairment","healthy ageing","gerontechnology","nutrition monitoring","dietary adherence","AI food recognition","Cantonese cuisine","brain health diet","feasibility study","acceptability study","Hong Kong older adults","2026-07-24",{"date":272,"type":41},"2026-07-29",{"date":162,"type":23},{"date":275,"type":23},"2028-02",{"name":277,"class":48},"Hong Kong Metropolitan University",{"id":279,"slug":280,"hasResults":12,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":17,"sex":18,"minAge":285,"maxAge":286,"enrollmentInfo":287,"targetDuration":4,"studyType":24,"phases":289,"briefSummary":290,"conditions":291,"keywords":294,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":49},"100378263","reactive-balance-training-for-fall-prevention-100378263","NCT04205279","Reactive Balance Training for Fall Prevention","Reactive Balance Training for Fall Prevention: a Comparative Study of Three Different Perturbation Devices","Inclusion Criteria:\n\nHealthy Young participants\n\n* Age group: 18-55 years.\n* Absence of any acute or chronic neurological, cardiopulmonary, musculoskeletal or systemic diagnosis.\n* No recent major surgery (\\\u003C 6 months) or hospitalization (\\\u003C 3 months)\n* Not on any sedative drugs.\n* Can understand and communicate in English\n\nHealthy older adults\n\n* Age group: 56-90 years.\n* Absence of any acute or chronic neurological, cardiopulmonary, musculoskeletal or systemic diagnosis.\n* No recent major surgery (\\\u003C 6 months) or hospitalization (\\\u003C 3 months)\n* Not on any sedative drugs.\n* Ability to walk with or without an assistive device for 10 meters\n* Can understand and communicate in English\n* Berg balance scale score \\\u003C45\u002F56.\n\nPersons with stroke\n\n* Age group: 18-90 years.\n* Absence of any acute or chronic neurological diagnosis except stroke (self reported)\n* Onset of stroke (\\> 6 months)\n* Absence of any cardiopulmonary, musculoskeletal or systemic diagnosis.\n* No recent major surgery (\\\u003C 6 months) or hospitalization (\\\u003C 3 months)\n* Not on any sedative drugs.\n* Ability to walk with or without an assistive device for 10 meters\n* Can understand and communicate in English\n\nExclusion Criteria:\n\nHealthy subject:\n\n* Subjects will not proceed with the test if any of the following occurs at baseline measurement: 1) HR \\> 85% of age-predicted maximal heart rate (HRmax) (HRmax = 220 - age), 2) systolic blood pressure (SBP) \\> 165 mmHg and\u002For diastolic blood pressure (DBP) \\> 110 mmHg during resting), and 3) oxygen saturation (measured by pulse oximeter) during resting \\\u003C 95%.\n* Body weight more than 250 lbs.\n\nHealthy Older adults:\n\n* Individuals with heel bone density with a T-score \\\u003C -2, is classified as osteoporotic and will be excluded.\n* Individuals with mild cognitive impairment (Mini-mental State Exam score \\\u003C 25\u002F30) will be excluded.\n* Subjects will not proceed with the test if any of the following occurs at baseline measurement: 1) HR \\> 85% of age-predicted maximal heart rate (HRmax) (HRmax = 220 - age), 2) systolic blood pressure (SBP) \\> 165 mmHg and\u002For diastolic blood pressure (DBP) \\> 110 mmHg during resting), and 3) oxygen saturation (measured by pulse oximeter) during resting \\\u003C 95%.\n* 6 minute walk test. Subjects will also be screened out if on the 6 minute walk test they complain of shortness of breath or uncontrolled pain (\\> 3\u002F10 on VAS) or pulse oxygen drops \\\u003C 92% or are unable to achieve the age-specified minimal ambulation distance.\n* Body weight more than 250 lbs.\n\nPersons with stroke:\n\n* Individuals with heel bone density with a T-score \\\u003C -2, is classified as osteoporotic and will be excluded.\n* Individuals with mild cognitive impairment (Mini-mental State Exam score \\\u003C 25\u002F30) will be excluded.\n* Subjects will not proceed with the test if any of the following occurs at baseline measurement: 1) HR \\> 85% of age-predicted maximal heart rate (HRmax) (HRmax = 220 - age), 2) systolic blood pressure (SBP) \\> 165 mmHg and\u002For diastolic blood pressure (DBP) \\> 110 mmHg during resting), and 3) oxygen saturation (measured by pulse oximeter) during resting \\\u003C 95%.\n* 6 minute walk test. Subjects will also be screened out if on the 6 minute walk test they complain of shortness of breath or uncontrolled pain (\\> 3\u002F10 on VAS) or pulse oxygen drops \\\u003C 92% or are unable to achieve the age-specified minimal ambulation distance.\n* Body weight more than 250 lbs.","18 Years","90 Years",{"count":288,"type":23},90,[26],"The objective of this pilot study is to evaluate and compare the effect of three different perturbation based training devices on the reactive balance control among healthy young adults, healthy older adults, and neurologically impaired stroke individuals. Furthermore, the project aims to determine the feasibility and tolerability of 30-minutes of perturbation training using the SureFooted Trainer. Overall, the project directs to find out the long term effect of training on fall risk reduction and fall prevention.\n\nThis study investigates the effects of perturbation training (slip and trip) based on the principles of motor learning. Perturbations in the form of slips and trips induced by the three different types of perturbation devices will displace the center of mass outside the base of support and challenge the stability, thereby inducing a fall and demand compensatory strategies in order to prevent it. Such perturbation training would train the motor system to improve stability control and vertical limb support.\n\nThe project design aims to examine the ability of the central nervous system to mitigate the interference in stability control (if any) that is induced by opposing types of perturbations. The hypothesis of this study if supported by the results, will provide the difference in motor learning with training on three different perturbation devices. Furthermore, it would help to determine which of the three training devices is the most effective in developing defense mechanisms necessary to reduce fall-risk among community-living older adults and the neurological population.",[292,29,293],"Healthy Young","Stroke",[295,296,297],"Reactive balance","Virtual reality training","Surefooted platform","2026-07-01",{"date":300,"type":41},"2026-07-06",{"date":302,"type":41},"2018-02-01",{"date":304,"type":23},"2027-12-31",{"name":306,"class":48},"University of Illinois at Chicago",{"id":308,"slug":309,"hasResults":12,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":314,"enrollmentInfo":315,"targetDuration":4,"studyType":24,"phases":317,"briefSummary":318,"conditions":319,"keywords":323,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":49},"100645084","evaluation-of-applex-apple-extract-on-anti-inflammatory-and-healthy-aging-effects-100645084","NCT07678346","Evaluation of AppleX™ Apple Extract on Anti-Inflammatory and Healthy Aging Effects","A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Evaluate the Anti-Inflammatory and Healthy Aging Effects of AppleX™ Apple Extract (15% Fisetin) in Adults 45-70 Years of Age","Inclusion Criteria:\n\n* Age 45-70 years at time of enrollment\n* Meets questionnaire-based inflammatory enrichment criteria (at least 2 of 5 risk factors, per Section 4.2)\n* Non-smoker (no tobacco or nicotine use within 6 months of enrollment)\n* Willing and able to maintain stable diet, exercise habits, and supplement use throughout the 24-week study period\n* No major medication changes planned during the study period\n* Willing to perform home-based DBS collections at T0, T12, and T24\n* Access to a smartphone or computer to complete eConsent and online questionnaires\n* Able to provide informed consent via the Alethios eConsent platform\n\nExclusion Criteria:\n\n* Current use of prescription anti-inflammatory medications including NSAIDs (regular use ≥3x\u002Fweek), corticosteroids, or DMARDs\n* Diagnosis of an autoimmune or inflammatory disease (e.g., rheumatoid arthritis, lupus, IBD, multiple sclerosis)\n* Active or unstable cardiovascular disease requiring medication changes during the study period\n* History of cancer within the past 5 years (except non-melanoma skin cancer)\n* Regular use of supplemental fisetin, quercetin, or resveratrol within 30 days of enrollment\n* Pregnancy, breastfeeding, or planning to become pregnant during the study\n* Known allergy to apple or apple-derived products\n* Body mass index (BMI) \\>40 kg\u002Fm²","70 Years",{"count":316,"type":23},70,[26],"The goal of this clinical trial is to learn if AppleX™ Apple Extract can help lower systemic inflammation in adults aged 45-70 with signs of low-grade inflammation. It will also look at the extract's effects on fatigue, joint comfort, and biological aging metrics.\n\nThe main questions it aims to answer are:\n\n* Does taking AppleX™ Apple Extract daily lower high-sensitivity C-reactive protein (hsCRP) levels, a key marker of inflammation in the blood?\n* Does AppleX™ Apple Extract improve participant-reported fatigue and joint comfort?\n* Does the extract slow down biological or epigenetic aging metrics compared to a placebo?\n\nResearchers will compare AppleX™ Apple Extract to a placebo (a look-alike capsule that contains no active ingredients) to see if the apple extract has a measurable anti-inflammatory and healthy aging effect.",[320,29,321,322],"Systemic Inflammation (hsCRP)","Vitality","Healthy Adult Participants",[324,325,326,327],"Apple extract","Fisetin","Flavonoids","polyphenols","2026-06-25",{"date":298,"type":41},{"date":331,"type":23},"2026-07",{"date":333,"type":23},"2027-02",{"name":335,"class":140},"Nutraland USA, Inc.",{"id":337,"slug":338,"hasResults":12,"nctId":339,"briefTitle":340,"officialTitle":340,"acronym":4,"eligibilityCriteria":341,"healthyVolunteers":17,"sex":18,"minAge":342,"maxAge":314,"enrollmentInfo":343,"targetDuration":4,"studyType":24,"phases":344,"briefSummary":345,"conditions":346,"keywords":348,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":360,"locationsCount":49},"100644843","effects-of-miricell-supplementation-on-biomarkers-of-healthy-aging-and-autophagy-100644843","NCT07675200","Effects of Miricell Supplementation on Biomarkers of Healthy Aging and Autophagy","INCLUSION CRITERIA:\n\n* Provide voluntary signed and dated informed consent.\n* Be in fair health as determined by medical history and routine blood chemistries.\n* Age between the ages of 40 and 70 (inclusive).\n* Body weight of at least 110 pounds.\n* Normotensive (seated, resting systolic blood pressure \\\u003C140 mm Hg and diastolic blood pressure \\\u003C 90 mm Hg. If the first measurement is slightly elevated above these limits, the subject will be given a brief (5-minute) rest period, and two more measurements will be taken. The average of all three measurements will be used to determine eligibility.\n* Normal seated, resting heart rate (\\\u003C90 per minute).\n* Willing to duplicate their previous 24-hour diet, refrain from alcohol for 24 hours, exercise for 24 hours prior to each trial, caffeine for 12 hours prior to each trial, and fast for 10 hours prior to each of the treatments.\n* Participant agrees to maintain existing dietary and physical activity patterns throughout the study period.\n* Participant is willing and able to comply with the study protocol.\n* If a dietary supplement was initiated within the past month, the participant is willing to discontinue supplement use followed by a 2-week washout prior to participation in the study.\n* Able to provide an adequate blood draw.\n\nEXCLUSION CRITERIA:\n\n* Use of probiotics, postbiotics or antibiotics within the past month.\n* A history of unstable or new-onset cardiovascular\u002Fcardiorespiratory, liver, or renal disease.\n* The participant's alcohol consumption is more than two standard alcoholic drinks per day or more than 10 drinks per week or has a history of drug\u002Falcohol abuse or dependence.\n* History of diabetes (any form) or any endocrine disorder.\n* Fasting blood sugar of \\> 125 mg\u002FdL.\n* Current smokers who smoke 11 or more cigarettes per day (i.e. light smokers will be enrolled if they meet all other criteria).\n* History of hyperparathyroidism or an untreated thyroid disease.\n* History of malignancy in the previous five years except for non-melanoma skin cancer (basal cell cancer or squamous cell cancer of the skin).\n* Chronic inflammatory condition or disease (e.g., rheumatoid arthritis, Crohn's Disease, ulcerative colitis, lupus, HIV\u002FAIDS, etc.).\n* Previous medical diagnosis of gout or fibromyalgia.\n* Any female who is pregnant, trying to become pregnant, is less than\u002For equal to 120 days postpartum, or any current women who are nursing.\n* Women who participate in this study must agree to the use of contraception for the duration of the study, and any sexually active woman will have to take a negative pregnancy test prior to enrolling. Women of childbearing age (any woman prior to menopause), regardless of their use of contraception, will be provided a urine pregnancy test kit at their screening visit and take the test in private using the female lavatory after signing an informed consent.\n* Known allergy or sensitivity to any ingredient in the test formulations as listed on the product label.\n* Any other diseases or conditions that, in the opinion of the medical staff, could confound the primary endpoints or place the subject at increased risk of harm if they were to participate.","40 Years",{"count":316,"type":23},[26],"The goal of this clinical trial is to learn if a dietary supplement called Miricell works to improve cellular health and signs of healthy aging in adults. It will also learn about the safety of Miricell.\n\nThe main questions it aims to answer are:\n\n* Does Miricell improve markers of autophagy, which is the body's natural process for recycling damaged cells?\n* Does Miricell support brain health, metabolic health, and visible signs of aging?\n* What medical problems, if any, do participants experience while taking Miricell?\n\nResearchers will compare Miricell to a placebo (a look-alike capsule that contains no active ingredients) to see if Miricell works better to support healthy aging.\n\nParticipants will:\n\n* Take either one Miricell capsule or a placebo every day for 12 weeks with a morning meal.\n* Visit the research clinic four times over the course of the study for checkups and tests.\n* Complete memory and thinking tests, track their daily physical activity, and give blood samples to measure health changes.",[347,29],"Autophagy",[349,350,351,352,353],"Spermidine","Polyamines","Cognitive Function","Miricell(R)","Cellular Health","2026-06-23",{"date":356,"type":41},"2026-06-30",{"date":358,"type":41},"2026-01-09",{"date":43,"type":23},{"name":335,"class":140},{"id":362,"slug":363,"hasResults":12,"nctId":364,"briefTitle":365,"officialTitle":366,"acronym":367,"eligibilityCriteria":368,"healthyVolunteers":17,"sex":18,"minAge":342,"maxAge":172,"enrollmentInfo":369,"targetDuration":4,"studyType":24,"phases":371,"briefSummary":372,"conditions":373,"keywords":375,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":389,"locationsCount":49},"100642223","multivitamin-and-mineral-supplementation-and-healthy-aging-100642223","NCT07642869","Multivitamin and Mineral Supplementation and Healthy Aging","The Impacts of Multivitamin and Mineral Supplementation on Cellular Metabolism and Healthy Aging","MiMIC","Inclusion Criteria:\n\n1. IPAQ-SF categorical score of low or moderate physical activity (indicating sedentary lifestyle).\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. Between 40-60 years of age\n4. BMI ≥18.5 and ≤32 kg\u002Fm2\n5. Weight stable for the prior 6 weeks\n\nExclusion Criteria:\n\n1. Is pregnant or nursing.\n2. Current smoker.\n3. Diabetes (FPG \\> 180 mg\u002FdL or A1c\\>8)\n4. Heart or cardiovascular condition, including coronary artery disease, congestive heart failure, diagnosed abnormality of heart rhythm, atrial fibrillation and\u002For a history of myocardial infarction\n5. Cancer or history of cancer within the past 5 years\n6. Sensory or physical impairment that would prevent participation\n7. Parkinson's disease, multiple sclerosis or other neurological condition, including a previous stroke, that may be causing impaired muscle function or mobility\n8. Consistent use of any multivitamin and mineral supplement use, or any supplement that may interfere with measurements or biological outcomes (including but not limited to: NAD+ supplements, MitoQ)\n9. Individuals with drug interactions as determined by the study physician",{"count":370,"type":23},150,[26],"The goal of this study is to determine the impact of MVM supplementation on clinical and biochemical markers associated with healthy aging, with a particular focus on mitochondrial function and metabolism. Specifically, changes in mitochondrial respiration using isolated blood cells will be measured. This method has been used to compare with various other age-related markers of health such as physical function, gait speed, and resting metabolic rate. It is hypothesize that MVM supplementation will impact the function of blood cells. MVM supplementation impacts other markers of health, including serum nutrient levels, metabolomic profiles, physical function, and skeletal muscle composition and quality will be explored. These comprehensive assessments will provide insights into the potential benefits of MVM supplementation for healthy aging and address critical gaps in our understanding of its immediate effects. Further, this study will aid in the understanding of how multivitamin supplements can support heathy aging in mid-life adults, a key time to start including wellness programs in people's lives.\n\nThe study cohort will consist of 150 sedentary men and women aged 40-60-years of age. A double-blind, three-arm, placebo-controlled randomized clinical trial will be conducted. Participants will receive a daily oral tablet containing one of two possible formulations of vitamins and minerals or a placebo. The three groups will be MVM \"GOLD\" blend formula, the US Restage MVM \"US CORE\", and the placebo group.",[29,374],"Multivitamin and Mineral Supplementation",[376,377,378,379,380,381],"Multivitamin and mineral supplements","Supplements","Cellular metabolism","healthy aging","mitochondria","Respirometry","2026-06-10",{"date":384,"type":41},"2026-06-15",{"date":386,"type":41},"2025-09-05",{"date":388,"type":23},"2026-12",{"name":390,"class":48},"University of California, San Diego",{"id":392,"slug":393,"hasResults":12,"nctId":394,"briefTitle":395,"officialTitle":396,"acronym":397,"eligibilityCriteria":398,"healthyVolunteers":17,"sex":399,"minAge":285,"maxAge":172,"enrollmentInfo":400,"targetDuration":4,"studyType":24,"phases":402,"briefSummary":404,"conditions":405,"keywords":4,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":418,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":424,"locationsCount":49},"100640820","phase-1-hormones-outcomes-and-pain-pathways-in-exercise-study-100640820","NCT07579182","Hormones, Outcomes, and Pain Pathways in Exercise Study","Mechanical and Non-mechanical Contributions to Chronic Neck, Shoulder, Arm, and Back Pain in Full-busted Women","HOPE","Inclusion Criteria:\n\n1. Able to provide informed consent\n2. Age of 18 to 60 years\n3. Assigned female sex at birth\n4. Right-handed by self-declaration\n5. Willing to participate in one online testing session and up to four in-person testing sessions\n6. Bra band size between 32-40\"\n7. International Physical Activity Questionnaire - Short Form (IPAQ-SF) score of 2 or higher\n8. An answer of \"NO\" to any item of the general health questions of the PARQ+\n9. No history of surgery to the: back, neck, or shoulders or joint replacement\n10. No history of implanted pacemakers or other stimulation devices\n11. No history of spinal cord injury (SCI)\n\nExclusion Criteria:\n\n1. Inability to provide informed consent\n2. Age 17 years old or younger or 61 years or older\n3. Assigned male sex at birth\n4. Left-handed by self-declaration\n5. Not willing to participate in one online testing session and up to four in-person testing sessions\n6. Bra band size greater than 40\" or less than 32\"\n7. IPAQ-SF score of 1 or lower\n8. An answer of \"YES\" to any item of the general health questions of the PARQ+\n9. History of limb amputation (upper or lower extremity)\n10. Presence of open pressure sores on the upper or lower extremities\n11. Currently pregnant or lactating\u002Fbreastfeeding\n12. History of surgery to the: back, neck, or shoulders or joint replacement\n13. History of breast cancer and\u002For mastectomy\n14. History of implanted pacemakers or other stimulation devices\n15. History of spinal cord injury (SCI)\n16. History of joint disease including osteoarthritis and\u002For Rheumatoid Arthritis\n17. History of the following neurological diseases: Cerebrovascular accident (CVA, stroke), Alzheimer's Disease (AD), Dementia (of any form), Huntington's Disease, Traumatic Brain Injury (TBI), Spinal cord injury (SCI), Multiple Sclerosis (MS), Parkinson's Disease (PD), Polio, Paraproteinaemic Demyelinating Neuropathy (PDN) and\u002For Monoclonal Gammopathy of Undetermined Significance (MGUS), Myasthenia Gravis, Muscular Dystrophy, Guillain-Barré Syndrome, Scoliosis, Charcot-Marie-Tooth Disorder or other hereditary neuropathies\n\nAdditional Inclusion Criteria for Intervention Group:\n\na. Self-declared breast size of D-I cup (US sizes: D, E, F, G, H)\n\nAdditional Inclusion Criteria for the Control Group:\n\na. Self-declared breast size of A-C cup (US sizes: AA, A, B, C)","FEMALE",{"count":401,"type":23},140,[403],"PHASE1","The goal of the proposed project is to evaluate a mechanical intervention (sports bras designed specifically for full busted women) to alleviate neck, shoulder, arm, and back pain in full-busted women and investigate the contribution of non-mechanical pathways associated with this type of pain in women. Specifically, the investigators will investigate how sex-hormones, inflammation, and remapping of specific regions of the brain contribute to the manifestation of neck, shoulder, arm, and back pain in full-busted women across the lifespan.",[406,407,408,409,410,411,412,29,413,152,414,415,416],"Breast Pain","Mastalgia","Back Pain","Back Pain, Low","Neck Pain","Chest Pain","Activity, Motor","Weight, Body","Gonadal Steroid Hormones","Neuronal Plasticity","Neuromuscular Manifestations","2026-05-28",{"date":419,"type":41},"2026-06-02",{"date":421,"type":41},"2026-05-17",{"date":423,"type":23},"2029-09",{"name":425,"class":48},"University of Houston",{"id":427,"slug":428,"hasResults":12,"nctId":429,"briefTitle":430,"officialTitle":430,"acronym":4,"eligibilityCriteria":431,"healthyVolunteers":17,"sex":18,"minAge":57,"maxAge":4,"enrollmentInfo":432,"targetDuration":4,"studyType":24,"phases":433,"briefSummary":434,"conditions":435,"keywords":440,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":452,"startDateStruct":454,"completionDateStruct":455,"leadSponsor":457,"locationsCount":49},"100640391","assessing-the-influence-of-habitual-beef-intake-on-key-molecular-markers-of-brain-health-100640391","NCT07623785","Assessing the Influence of Habitual Beef Intake on Key Molecular Markers of Brain Health","Inclusion Criteria:\n\nAdults aged 65 years and older.\n\nGenerally healthy with no acute illnesses.\n\nFluent in English.\n\nWilling to consume lean beef and dairy products (cottage cheese and whey protein) daily during the intervention phases.\n\nWilling to maintain current, habitual diet, physical activity levels, and body weight throughout the study.\n\nWilling to fast for 12 hours prior to clinical visits and provide blood, urine, stool, and saliva samples.\n\nExclusion Criteria:\n\nDiagnosed with Alzheimer's disease, Parkinson's disease, or other severe cognitive disorders.\n\nHistory of gastrointestinal diseases (e.g., Crohn's disease, celiac disease) or major gastrointestinal surgery.\n\nUncontrolled diabetes, severe liver or kidney disease, or a recent cardiovascular event (within the past 6 months).\n\nAllergies or severe intolerances to beef or dairy, or adherence to a strict vegetarian or vegan diet.\n\nBody weight fluctuation of \\>5% within the past 3 months.\n\nUse of systemic antibiotics within the 2 months prior to baseline.\n\nCurrent heavy smoking or excessive alcohol consumption.",{"count":243,"type":23},[26],"his study investigates whether eating lean beef every day can help support brain health and healthy aging in older adults. As people age, protecting memory and cognitive function becomes increasingly important. Lean beef is a rich source of essential nutrients-such as vitamin B12, iron, zinc, and creatine-that are known to support brain function. However, the direct biological effects of a beef-rich diet on brain health markers are not fully understood.\n\nIn this study, researchers will recruit 20 generally healthy older adults (aged 65 and older) to participate in a dietary feeding trial. Participants will complete two separate 2-week dietary phases. During one phase, participants will consume 5.5 ounces (156 grams) of provided lean beef daily. During the other phase, they will consume an iso-caloric, protein-matched, non-beef control food daily. A two-week \"washout\" period, where participants return to their normal diets, will separate the two phases to ensure there are no overlapping effects.\n\nResearchers will collect blood, urine, stool, and saliva samples at the beginning and end of each 2-week dietary phase. These samples will be analyzed to see if the lean beef diet improves specific biological markers in the blood related to memory, nerve protection, and overall brain aging. Ultimately, the findings from this study will help determine if incorporating lean beef into a regular diet can be a natural, food-based strategy to help preserve neurological health in older adults.",[29,436,437,438,439],"Brain Health","Cardiometabolic Health","Normal Aging","Cognitive Decline Prevention in Robust Older Adults",[441,442,443,444,445,446,447,448,257,449,450,451],"lean beef","red meat","dietary intervention","brain biomarkers","p-tau217","amyloid beta","bdnf","lipidomics","neuroprotection","nutrition","metabolomics",{"date":453,"type":41},"2026-06-03",{"date":453,"type":23},{"date":456,"type":23},"2027-07-31",{"name":458,"class":48},"South Dakota State University",{"id":460,"slug":461,"hasResults":12,"nctId":462,"briefTitle":463,"officialTitle":464,"acronym":465,"eligibilityCriteria":466,"healthyVolunteers":17,"sex":18,"minAge":115,"maxAge":4,"enrollmentInfo":467,"targetDuration":4,"studyType":24,"phases":469,"briefSummary":470,"conditions":471,"keywords":476,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":482,"lastUpdatePostDateStruct":483,"startDateStruct":485,"completionDateStruct":487,"leadSponsor":489,"locationsCount":49},"100640034","sheba-healthspan-research-population-sharp-trial---sheba-longevity-center-diagnostic-and-intervention-protocol-to-lower-biological-age-in-older-adults-100640034","NCT07596576","Sheba Healthspan Research Population (SHARP) Trial - Sheba Longevity Center Diagnostic and Intervention Protocol to Lower Biological Age in Older Adults","Sheba Healthspan Research Population (SHARP) Trial","SHARP","Inclusion Criteria:\n\n* Healthy older adults \\>50 years old men and women\n\nExclusion Criteria:\n\n1. A former diagnostic of a significant cognitive reduction (MoCa score \\\u003C 24 ).\n2. Former diagnosis of neurodegenerative disease as Alzheimer's disease, Parkinson's disease, Lewy body dementia.\n3. Former diagnosis of psychiatric disease.\n4. In the past two years, underwent chemotherapy or radiation therapy.",{"count":468,"type":23},1500,[26],"Background: Population aging is accelerating rapidly in Israel and worldwide, necessitating adaptation of the healthcare system and considering new approaches that serve the needs of older adult populations.\n\nWorking hypothesis and aims: We hypothesize that a personalized health and behavior intervention program will decrease the biological age as assessed by several biological aging clocks and improve functional and cognitive performance among older adults.\n\nMethods: We propose to conduct a randomized study among healthy community-dwelling elderly subjects (\\>50 years old). The study will include an extensive aging assessment and imaging protocol (baseline assessment), including comprehensive physical, functional, sensory, cognitive, and mental assessment. Each participant in the intervention group will receive a personalized intervention program based on an integrative systems approach analysis. In addition, a uniquely developed application will track compliance and monitor physiological data through a provided wearable device. The control group will be assessed at baseline without receiving an intervention program. Each participant will visit the center aging after 6 months for a blood test and after 12 months for a second extensive diagnostic protocol, similar to the baseline assessment protocol. About 1,500 subjects will be recruited to participate in the study.\n\nExpected results: Obtaining data at two points will allow us to examine efficiency and compliance with a personalized intervention program based on integrative systems analysis models. We expect biological age, general well-being, and various clinical and psychosocial outcomes in the intervention group will decrease and improve compared to the control group.\n\nStudy importance and relevance: The obtained results may help establish evidence-based healthy aging diagnostics protocols and an effective personalized intervention program that might be applied, with proper modifications, to national healthcare organizations for the general older adult population. In addition, to provides a scientific basis on which policymakers and intervention programs can rely to develop national guidelines for promoting extended health.",[29,472,473,474,475],"Healthspan","Biological Age","Intrinsic Capacity","Immunaging",[477,478,479,480,481],"healthy longevity","healthspan","geromedicine","biological age","health trajectories","2026-05-18",{"date":484,"type":41},"2026-05-19",{"date":486,"type":41},"2024-03-01",{"date":488,"type":23},"2027-12-01",{"name":490,"class":491},"Sheba Medical Center","OTHER_GOV",{"id":493,"slug":494,"hasResults":12,"nctId":495,"briefTitle":496,"officialTitle":497,"acronym":498,"eligibilityCriteria":499,"healthyVolunteers":17,"sex":18,"minAge":84,"maxAge":20,"enrollmentInfo":500,"targetDuration":4,"studyType":244,"phases":4,"briefSummary":502,"conditions":503,"keywords":509,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":482,"lastUpdatePostDateStruct":527,"startDateStruct":529,"completionDateStruct":531,"leadSponsor":532,"locationsCount":4},"100639073","meva-cognitive-wellness-platform-study-for-adults-100639073","NCT07595250","MEVA Cognitive Wellness Platform Study for Adults","Phase 1 Validation Study of the MEVA Cognitive Wellness Platform","MEVA","Inclusion Criteria:\n\n* Adults aged 55 to 75 years\n* Community-dwelling (living independently in the community)\n* English fluency sufficient for informed consent, task instructions, and questionnaires\n* Able to provide informed consent using teach-back method\n* Able to use a computer or tablet for simple tap or drag interactions\n* Functional vision sufficient for on-screen tasks with usual corrective lenses\n* Functional hearing sufficient for spoken instructions with or without hearing aids\n* Interest in cognitive wellness and personal well-being\n* Available for baseline visit and possible retest visit approximately 14 days later\n* Transportation to study site or ability to participate remotely if permitted by protocol\n* Assistive devices and accommodations are permitted\n\nExclusion Criteria:\n\n* Severe visual impairment preventing completion of digital tasks\n* Severe motor impairment preventing interaction with tablet or web application\n* Known diagnosis of moderate or severe dementia, or inability to comprehend consent and task instructions\n* Current participation in another cognitive training or technology intervention study likely to confound outcomes\n* Recent hospitalization, emergency room visit, or acute exacerbation of a medical or psychiatric condition within the past 30 days that would impede study participation\n* Current substance use disorder likely to interfere with study adherence or completion\n* Recent intensive use of a similar structured cognitive wellness or brain training application",{"count":501,"type":23},100,"The goal of this observational study is to evaluate the reliability, usability, and feasibility of the MEVA Cognitive Wellness Platform in community-dwelling adults aged 55 to 75.\n\nThe main questions it aims to answer are:\n\nHow consistent is the MEVA Global Cognitive Index when participants complete the MEVA activities again approximately 14 days later? How usable and acceptable is the MEVA platform for older adults in community settings? What completion rates, data quality patterns, and participant feedback are observed during use of the platform?\n\nParticipants will:\n\nComplete a baseline study visit lasting approximately 45 to 60 minutes Complete a 7-activity digital cognitive wellness battery Answer questionnaires about usability, technology acceptance, and wellness experience Complete the Saint Louis University Mental Status (SLUMS) examination as an exploratory comparison measure If selected for the retest group, return approximately 14 days later to complete the MEVA activities again\n\nMEVA is being evaluated as a cognitive wellness platform. It is not intended to diagnose, treat, prevent, screen for, or monitor any disease or medical condition.",[504,29,505,97,506,507,508],"Cognitive Wellness","Age-Related Cognitive Change","Cognitive Change","Health Behavior","Primary Care",[510,155,511,512,513,514,515,516,517,518,519,520,521,522,523,524,525,526],"Cognitive wellness","Health equity","Test-retest reliability","Community-dwelling older adults","Primary care","Digital wellness","Older adult engagement","Psychometrics","Usability","Community health","Wellness tracking","Cognitive engagement","Adult development","General wellness","Montessori-informed activities","Technology acceptance","Exploratory convergent validity",{"date":528,"type":41},"2026-05-20",{"date":530,"type":23},"2026-05",{"date":388,"type":23},{"name":533,"class":140},"Mentage LLC",{"id":535,"slug":536,"hasResults":12,"nctId":537,"briefTitle":538,"officialTitle":539,"acronym":4,"eligibilityCriteria":540,"healthyVolunteers":17,"sex":18,"minAge":172,"maxAge":4,"enrollmentInfo":541,"targetDuration":542,"studyType":244,"phases":4,"briefSummary":543,"conditions":544,"keywords":546,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":553,"lastUpdatePostDateStruct":554,"startDateStruct":555,"completionDateStruct":557,"leadSponsor":559,"locationsCount":49},"100610829","digital-technology-for-active-and-healthy-ageing-in-taiwan-100610829","NCT07232667","Digital Technology for Active and Healthy Ageing in Taiwan","Healthy Taiwan Cultivation Plan: Building an Active-ageing Lifestyle in Rural Taiwan Through Integrating Novel Healthcare Technology - From Mitigating Digital and Health Literacy Gap, Establishing a Mobile Interactive Pro-active-ageing Information Platform, to Exploring Multi-dimensional Digital Biomarkers of Ageing","Inclusion Criteria:\n\n1. Currently living or receiving care in a stable environment for at least four weeks prior to enrollment:\n\n   * For community-based participants: must have resided at the same address for ≥4 weeks.\n   * For day-care participants: must have attended activities at the same dementia or elderly day-care center for ≥4 weeks.\n2. Able and willing to participate in the study procedures.\n3. Informed consent must be obtained before participation.\n\n   * If the participant's cognitive function has declined to a level that prevents self-consent, written consent will be obtained from a legally authorized representative or primary caregiver.\n\nExclusion Criteria:\n\n1. Unstable physical or psychological condition that makes participation unsafe, as determined by a clinical investigator - e.g., acute delirium or current respiratory infection (including COVID-19).\n2. Any known allergy or skin sensitivity to the materials used in the Geneactiv actigraphy device or iCue sensor pad.\n3. Any other medical, neurological, or behavioral condition deemed unsuitable for participation by the study physician.",{"count":401,"type":23},"2 Weeks","Taiwan is entering a super-aged society in 2025, with more than 20% of the population aged 65 years or older. This rapid demographic shift, combined with increasing rates of chronic diseases, frailty, and dementia, has created growing challenges for healthcare and caregiving systems. Yunlin County, particularly its coastal region, has been one of Taiwan's earliest super-aged areas, showing higher rates of diabetes (10.5%), hypertension (28%), hyperlipidemia (26%), dementia (8%), and depression (12%) compared with national averages. Lifestyle factors such as tobacco (30%), betel nut (8%), and alcohol (15%) use are also more prevalent among local residents.\n\nFrom 2022 to 2024, health screenings at CMU Beigang Hospital revealed a 36.1% abnormality rate among 12,222 visits, while another 5,965 assessments from the county's ICOPE program showed similarly high rates. Many older adults, particularly retired agricultural and fishing workers, experience sedentary lifestyles and polypharmacy-related risks, which worsen frailty, insomnia, depression, and cognitive decline. Low general and digital health literacy further limits their ability to adopt preventive behaviors, forming a vicious cycle between poor health and aging.\n\nTo address these challenges, the Ministry of Health and Welfare launched the \"Healthy Taiwan Cultivation Plan.\" In alignment with this initiative, this project-led by CMU Beigang Hospital in collaboration with the National Health Research Institutes-aims to develop a wearable- and mobile-based health promotion model for rural older adults. The study will integrate research-grade actigraphy (Geneactiv), a mobile health platform (\"iMED\"), and the in-bed sensor iCue to monitor behavior, promote active aging, and enhance health and digital literacy. Ultimately, this project seeks to establish Taiwan's first integrated digital aging database and identify digital biomarkers for predicting cognitive and functional decline in older adults.",[29,545],"Digital Health Literacy",[547,548,549,155,550,551,552],"Elderly people","Wearable technology","Digital health literacy","Health literacy","Digital gap","Digital biomarkers","2026-05-15",{"date":482,"type":41},{"date":556,"type":41},"2026-04-22",{"date":558,"type":23},"2029-12-31",{"name":560,"class":48},"China Medical University Hospital",{"id":562,"slug":563,"hasResults":12,"nctId":564,"briefTitle":565,"officialTitle":566,"acronym":567,"eligibilityCriteria":568,"healthyVolunteers":17,"sex":18,"minAge":57,"maxAge":4,"enrollmentInfo":569,"targetDuration":4,"studyType":24,"phases":571,"briefSummary":572,"conditions":573,"keywords":574,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":585,"lastUpdatePostDateStruct":586,"startDateStruct":587,"completionDateStruct":589,"leadSponsor":590,"locationsCount":592},"100637398","computerized-cognitive-training-in-healthy-older-adults-and-mild-cognitive-impairment-100637398","NCT07598409","Computerized Cognitive Training in Healthy Older Adults and Mild Cognitive Impairment","Computerized Executive Function Training in Healthy Older Adults and Individuals With Mild Cognitive Impairment: Transfer Effects on Memory and Emotional Outcomes. A Randomized Controlled Trial","COGNI-AGE","Inclusion Criteria:\n\n1. adults 65 years of age and older;\n2. spanish speakers;\n3. residents in Spain (urban and rural communities);\n4. elderly population that does not have dementia or other major diagnosed uncontrolled neurological disorders;\n5. the initial cognitive state will be determined by a global screening test, the Lobo's Mini Cognitive Examination, that is, the spanish version of the Mini-Mental State Examination (MMSE); and 6) all participants must provide their signed written informed consent indicating that the individual has been informed of the relevant aspects of the study (and may withdraw from the study at any time if they so request).\n\nExclusion Criteria:\n\n1. Older adults who obtain scores indicative of severe impairment (to be determined for low MEC scores that are suggestive of incipient dementia) or whose medical condition prevents them from participating safely;\n2. diagnosis of dementia (e.g., Alzheimer's disease or other);\n3. uncontrolled active major psychiatric illness (major depression, schizophrenia, etc.);\n4. significant uncontrolled neurological conditions or history (e.g., Parkinson's disease, stroke, severe traumatic brain injury);\n5. uncontrolled decompensated chronic medical conditions (e.g., diabetes, cardiovascular disease) that may affect cognition or attendance at sessions; and 6) severe uncorrected sensory disabilities (e.g., blindness or severe hearing loss) that interfere with the performance of tasks on tablets.",{"count":570,"type":23},156,[26],"The overall objective of this study is to assess the effect of an adaptive computerized cognitive training program for executive functions (CogniFit platform) on improving these functions in older adults, both healthy and with mild cognitive impairment (MCI), as well as to examine the potential transfer effects of this training on memory. Additionally, determine the impact of the intervention on the emotional symptoms, behavioral disorders, or quality of life of the participants.",[247,29],[575,576,577,578,579,580,581,582,583,131,584],"Computarized Cognitive Training","Healthy Cognition","Mild Cognitive Impairment","Older adults","Cognition","Executive functions","Transfer","Emotional symptoms","Behavioral disorders","Memory","2026-05-13",{"date":528,"type":41},{"date":588,"type":41},"2025-06-04",{"date":137,"type":23},{"name":591,"class":48},"Universidad Antonio de Nebrija",2,{"id":594,"slug":595,"hasResults":12,"nctId":596,"briefTitle":597,"officialTitle":598,"acronym":4,"eligibilityCriteria":599,"healthyVolunteers":17,"sex":18,"minAge":115,"maxAge":4,"enrollmentInfo":600,"targetDuration":4,"studyType":24,"phases":602,"briefSummary":603,"conditions":604,"keywords":606,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":614,"lastUpdatePostDateStruct":615,"startDateStruct":616,"completionDateStruct":618,"leadSponsor":619,"locationsCount":49},"100636576","exoskeleton-assisted-mobility-in-aging-and-in-parkinsons-disease-100636576","NCT07567482","Exoskeleton-Assisted Mobility in Aging and in Parkinson's Disease","Exoskeleton-Assisted Mobility in Aging and in Parkinson's Disease: A Mixed-Methods Study of Effectiveness and Acceptability","Participants with Parkinson's disease\n\nInclusion Criteria:\n\n* Ability to walk for at least 30 minutes with or without minimal aid\n* Diagnosis of idiopathic Parkinson's disease\n* Hoehn and Yahr stage 1 to 4\n\nExclusion Criteria:\n\n* Height smaller than 152 cm\n* Severe vascular conditions of the lower limbs that may limit mobility or pose a risk.\n* Presence of any implantable or external life-sustaining medical device such as a pacemaker\n* Severe osteoporosis or high risk of fractures\n* Contra-indication to the required physical effort\n* Severe cognitive impairment (MoCA \\\u003C 21)\n* Presence of neurological disorders, lower-limb injuries, or other conditions interfering with mobility, other than Parkinson's disease.\n\nHealthy elderly participants without Parkinson's disease\n\nInclusion Criteria:\n\n* Ability to walk for at least 30 minutes with or without minimal aid\n* Age ≥ 65 years old\n\nExclusion Criteria:\n\n* Height smaller than 152 cm\n* Severe vascular conditions of the lower limbs that may limit mobility or pose a risk.\n* Presence of any implantable or external life-sustaining medical device such as a pacemaker\n* Severe osteoporosis or high risk of fractures\n* Contra-indication to the required physical effort\n* Severe cognitive impairment (MoCA \\\u003C 21)\n* Presence of neurological disorders, lower-limb injuries, or other conditions interfering with mobility",{"count":601,"type":23},26,[26],"This study will evaluate whether a wearable robotic exoskeleton can improve mobility, balance, and walking in healthy older adults and in individuals living with Parkinson's disease, populations at high risk of falls and mobility limitations. Participants will attend two laboratory sessions. The first session includes clinical assessments, fitting and familiarization with the exoskeleton, and interviews to explore user perceptions. The second session involves performing functional mobility tasks (e.g., walking, standing, turning) with and without the exoskeleton and under different assistance levels, while movement is measured using wearable sensors.\n\nThe study will assess the immediate effects of the exoskeleton on mobility, compare assistance levels, identify which participants benefit most, and explore user experience and acceptability. Findings will help inform the development and implementation of assistive technologies to support mobility in healthy aging and in individuals with Parkinson's disease.",[605,29],"Parkinson's Disease (PD)",[607,608,609,610,611,612,613],"Exoskeleton","Mobility","Rehabilitation","Parkinson's Disease","Walking","Balance","Risk of falls","2026-05-11",{"date":585,"type":41},{"date":617,"type":41},"2026-04-30",{"date":209,"type":23},{"name":620,"class":491},"Centre intégré de santé et de services sociaux de l'Outaouais",{"id":622,"slug":623,"hasResults":12,"nctId":624,"briefTitle":625,"officialTitle":626,"acronym":4,"eligibilityCriteria":627,"healthyVolunteers":17,"sex":18,"minAge":172,"maxAge":4,"enrollmentInfo":628,"targetDuration":4,"studyType":244,"phases":4,"briefSummary":630,"conditions":631,"keywords":4,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":635,"lastUpdatePostDateStruct":636,"startDateStruct":638,"completionDateStruct":640,"leadSponsor":641,"locationsCount":49},"100568198","swallowing-impairments-in-adults-with-and-without-alzheimers-disease-100568198","NCT06678100","Swallowing Impairments in Adults With and Without Alzheimer's Disease","Prevalence and Care Partner Burden of Individuals With Alzheimer's Disease","Inclusion criteria for AD cohort:\n\n1. adult ≥60 years old\n2. diagnosis of AD by a neurologist (confirmed with imaging, spinal tap, behavioral testing)\n3. no prior history of other neurological diseases (aside from stroke which has resolved with no current symptoms)\n4. no prior history of respiratory diseases\n5. no prior history of head and neck surgery\u002Fhead and neck cancer\u002Fradiation to head and neck region\n6. consuming some form of oral intake\n7. able to follow basic directions\n8. able\u002Fwilling to provide consent\u002Fassent.\n\nExclusion Criteria for AD Cohort:\n\n1. individual \\\u003C60 years old\n2. Diagnosis of another type of dementia\n3. History of neurological\u002Frespiratory diseases\n4. History of head and neck surgery\u002Fhead and neck cancer\u002Fradiation to head and neck region\n5. not consuming any oral intake\n6. Unable to follow basic directions\n7. Unable to provide consent based on the University of California, San Diego Brief Assessment of Capacity to Consent (UBACC), score \\\u003C15 OR provide assent and a legal guardian\u002Fhealth care decision maker provides consent.\n\nInclusion criteria for care partners of individuals with AD will be:\n\n1. care partner of an individual with AD\n2. willing to complete questionnaires\u002Fparticipate in an interview.\n\nExclusion Criteria for Caregivers of Individuals with AD:\n\n1. not the primary caregiver of an individual with AD\n2. unwilling to complete questionnaires\u002Fsemi-structured interview\n\nInclusion criteria for community-dwelling adults will be:\n\n1. adult ≥60 years old\n2. no prior history of neurological diseases (aside from stroke which has resolved with no current symptoms)\n3. no prior history of respiratory diseases\n\n3\\) no prior history of head and neck surgery\u002Fhead and neck cancer\u002Fradiation to head and neck region 4) no prior history of swallowing difficulties based on participant report. 5) Score ≥25th percentile based on sex\u002Fage\u002Feducation\u002Frace on the Montreal Cognitive Assessment (MOCA)\n\nExclusion Criteria for Healthy Cohort:\n\n1. individual \\\u003C60 years old\n2. history of neurological disease\n3. history of respiratory disease\n4. history of head and neck surgery\u002Fhead and neck cancer\u002Fradiation to head and neck region\n5. history of swallowing difficulties\n6. Score \\\u003C25th percentile based on sex\u002Fage\u002Feducation\u002Frace on the Montreal Cognitive Assessment (MOCA)",{"count":629,"type":23},240,"This research study is investigating whether people with Alzheimer's disease (AD) experience more changes to swallowing than their healthy age-matched peers. The prevalence of swallowing impairments in moderate-severe AD is high (85-93%), yet little is known about how swallow function evolves throughout the disease course in people with AD. The overall objective of this study is to evaluate swallowing function in adults with and without Alzheimer's disease. The investigator will also be involving the primary caregivers of individuals with Alzheimer's that are enrolled in the study to better understand the impact of swallowing impairments on the primary caregivers of those with Alzheimer's Disease.\n\nHealthy adults and individuals with Alzheimer's disease will:\n\n* undergo tests of cough and swallow function\n* undergo tests of grip and tongue strength\n* complete questionnaires\n\nCaregivers of individuals with Alzheimer's disease will also complete questionnaires.",[632,633,29,634],"Alzheimer Disease","Caregiver Burden","Dysphagia","2026-05-06",{"date":637,"type":41},"2026-05-08",{"date":639,"type":41},"2025-04-21",{"date":275,"type":23},{"name":642,"class":48},"Vanderbilt University Medical Center",{"id":644,"slug":645,"hasResults":12,"nctId":646,"briefTitle":647,"officialTitle":648,"acronym":649,"eligibilityCriteria":650,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":651,"targetDuration":4,"studyType":24,"phases":652,"briefSummary":653,"conditions":654,"keywords":659,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":661,"lastUpdatePostDateStruct":662,"startDateStruct":664,"completionDateStruct":666,"leadSponsor":667,"locationsCount":592},"100509058","african-americans-aa-communities-speak-100509058","NCT05908487","African Americans (AA) Communities Speak","African Americans (AA) Communities Speak: Partnering With AA in the North and South to Train Palliative Care Clinicians to Address Interpersonal and Systemic Racism and Provide Culturally Aligned Care.","AACS","Inclusion Criteria: Aim 1.1\n\nPerson with serious Illness:\n\n* Self-identified as African American (i.e., born, raised, and lived primarily in the US)\n* Non-Hispanic or Latino\n* Age ≥60 years\n* English-speaking\n* Has been diagnosed with a condition that fits into one of 3 illness paradigms including cancer, cardiac disease, pulmonary disease, neuro-degenerative disease, renal disease, stroke, sepsis, hepatic disease)\n* Callahan Six-Item Screener score ≥4\n* Able to complete baseline surveys.\n\nBereaved family member:\n\n* Self-identified as African American (i.e., born, raised, and lived primarily in the US)\n* Non-Hispanic or Latino\n* Age ≥60 years\n* English-speaking\n* Loved one dies in the last 12 months and was diagnosed with a condition that fits into one of 3 illness paradigms including cancer, cardiac disease, pulmonary disease, neuro- degenerative disease, renal disease, stroke, sepsis, hepatic disease)\n* Callahan Six-Item Screener score ≥4\n* Able to complete baseline surveys.\n\nExclusion Criteria\n\nPerson with serious illness:\n\n-Cannot be receiving hospice care\n\nBereaved Family Member:\n\n-Cannot be a paid \"sitter\"\n\nInclusion Criteria: Aim 1.2\n\nBereaved Family member:\n\n* Self-identified as African American (i.e., born, raised, and lived primarily in the US)\n* Non-Hispanic or Latino\n* Age ≥60 years\n* English-speaking\n* Loved one dies in the last 12 months and was diagnosed with a condition that fits into one of 3 illness paradigms including cancer, cardiac disease, pulmonary disease, neuro- degenerative disease, renal disease, stroke, sepsis, hepatic disease)\n* Callahan Six-Item Screener score ≥4\n* Able to complete baseline surveys\n\nPastors:\n\n* Self-identifying as African American\n* White, Non-Hispanic or Latino\n* Sged ≥18 years old.\n\nInclusion Criteria: Aim 3\n\nClinician eligibility:\n\n* Practice at a University of Alabama at Birmingham (UAB) or Montefiore\u002FEinstein site that provides care to patients eligible for outcomes surveys\n* At least 3 months of clinical practice at the study site prior to the intervention training to measure pre-intervention patient surveys\n\nExclusion criteria:\n\n-Lack of at least 3 months of clinical practice at the study site prior to the intervention training.\n\nPatient eligibility:\n\n* Self-identified as African American (i.e., born, raised, and lived primarily in the US)\n* Non-Hispanic or Latino, 3. age ≥60 years\n* English-speaking\n* Has been diagnosed with a condition that fits into one of 3 illness paradigms including cancer, cardiac disease, pulmonary disease, neuro-degenerative disease, renal disease, stroke, sepsis, hepatic disease)\n* Callahan Six-Item Screener score ≥4\n* Able to complete baseline surveys.\n\nExclusion criteria include:\n\n-Currently receiving hospice care.\n\nFamily member eligibility:\n\n* Age ≥ 18 years\n* English-speaking\n* Community-dwelling\n* Unpaid care provider of a person with a serious illness.\n\nExclusion criteria: 1. Cannot be a paid \"sitter\".",{"count":60,"type":23},[26],"African Americans are less likely to receive quality end-of-life (EoL) care. Addressing disparities in EoL care will need efforts to support a better understanding of African American patients' EoL cultural values and preferences for EoL communication and the impact of historical and ongoing care delivery inequities in healthcare settings.\n\nOur proposed \"Caring for Older African Americans\" training program is designed to empower clinicians to improve goal-concordant EoL care delivery by using community-developed storytelling videos to create empathy with experiences of racism in EoL care, guidelines for culturally concordant EoL care delivery, and an implicit bias recognition and management training to mitigate bias in goals of care communication.",[29,655,656,657,658],"Health Knowledge, Attitudes, Practice","Social Responsibility","Care Eliciting Behavior","Racism, Systemic",[660],"goal concordant care older African American CBPR end-of-life","2026-05-05",{"date":663,"type":41},"2026-05-07",{"date":665,"type":41},"2025-02-27",{"date":45,"type":23},{"name":668,"class":48},"University of Alabama at Birmingham",{"id":670,"slug":671,"hasResults":12,"nctId":672,"briefTitle":673,"officialTitle":674,"acronym":675,"eligibilityCriteria":676,"healthyVolunteers":17,"sex":18,"minAge":285,"maxAge":4,"enrollmentInfo":677,"targetDuration":679,"studyType":244,"phases":4,"briefSummary":680,"conditions":681,"keywords":683,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":690,"lastUpdatePostDateStruct":691,"startDateStruct":692,"completionDateStruct":694,"leadSponsor":696,"locationsCount":49},"100639408","russ-age-creating-of-a-biological-age-calculator-and-study-of-aging-phenotypes-in-the-russian-population-100639408","NCT07574359","RUSS-AGE: Creating of a Biological Age Calculator and Study of Aging Phenotypes in the Russian Population","RUSS-AGE, CREATING OF A BIOLOGICAL AGE CALCULATOR AND STUDY OF AGING PHENOTYPES IN THE RUSSIAN POPULATION","RUSS-AGE","Inclusion Criteria: Signing the informed consent form to participate in the study.\n\nParticipant's age was 18 years or older at the time of inclusion in the study.\n\n\\-\n\nExclusion Criteria:\n\n1. Refusal to participate in the study or to provide informed consent.\n2. History or medical records indicating the presence of infectious diseases (Hepatitis C, Hepatitis B, including HBsAg carrier status, HIV infection).\n3. Presence of an acute illness\u002Fcondition, exacerbation of a chronic disease, or surgical intervention within the last month prior to study inclusion.\n4. Lack of remission from an oncological disease or ongoing anti-tumor therapy initiated less than three years prior to study inclusion.\n5. Severe cognitive or sensory impairments and mental disorders that, in the investigator's opinion, preclude adequate communication with the subject.\n6. Severe forms of chronic non-communicable diseases: life-threatening cardiac arrhythmias, chronic heart failure NYHA Class III-IV, left ventricular ejection fraction \\\u003C40%, ischemic heart disease CCS Class III-IV, chronic kidney disease Stages 4-5, type 1 diabetes mellitus, type 2 diabetes mellitus with terminal stages of complications, systemic connective tissue diseases, chronic obstructive pulmonary disease with respiratory failure of Grade 1 or higher, bronchial asthma requiring glucocorticosteroid therapy, osteoarthritis Kellgren-Lawrence Grade IV, body mass index (BMI) ≥40 kg\u002Fm², as well as documented history of myocardial infarction (MI) or acute cerebrovascular accident (stroke).\n7. Pregnancy or lactation (breastfeeding).\n8. Any other factors that, in the investigator's opinion, may preclude the participant's inclusion in the study.\n\n   Additional exclusion criteria for participants undergoing stool sample collection:\n9. Use of systemic antibiotics for 3 or more days within the 3 months prior to the study start.\n10. Any invasive procedures on the large intestine within the last 3 weeks prior to the study start.",{"count":678,"type":23},3500,"2 Years","This is a multi-center, cross-sectional, observational study aimed at developing biological age calculators specifically for the Russian population investigating various aging phenotypes.\n\nAging is a complex process that varies greatly between individuals, meaning that chronological age does not always reflect one's biological health status. The primary goal of this study is to identify and analyze a comprehensive set of markers (including socioeconomic factors, lifestyle, physical parameters, cognitive function, and laboratory biomarkers) that best reflect the aging process. Using this data, researchers will create a mathematical model to estimate a person's \"biological age.\"\n\nThe study plans to enroll at least 3,500 male and female volunteers aged 18 years and older from across Russia. Participants will be divided into 5-year age groups (e.g., 18-24, 25-29, up to 90+ years) to ensure broad representation.\n\nParticipation involves a single visit to a clinical center. During this visit, participants will undergo:\n\nInterview and questionnaires (assessing health history, lifestyle, socioeconomic status, diet, sleep, and quality of life).\n\nPhysical examination and anthropometric measurements (height, weight, blood pressure, grip strength).\n\nFunctional and cognitive tests (e.g., walking speed, balance tests, memory and attention tasks tailored to age).\n\nCollection of biomaterials: blood (50 ml), urine, and stool samples for extensive laboratory analysis, including routine tests and specialized aging biomarkers. Part of the biomaterials will be biobanked for future scientific research.\n\nInstrumental examinations for a subset of participants: Depending on the center's capabilities and the study protocol, some participants may also undergo additional assessments such as densitometry (bone density scan), bioimpedance analysis (body composition), and brain MRI.\n\nThe results are expected to lead to the creation of a validated biological age calculator for the Russian population. This tool could help identify targets for interventions to promote healthy aging and, in the future, potentially predict the risk of developing age-related chronic diseases.",[29,682],"Biomarkers",[480,684,685,686,687,688,379,689],"aging biomarkers","aging clock","biological age calculator","phenotypic age","aging phenotype","machine learning in aging","2026-05-04",{"date":663,"type":41},{"date":693,"type":41},"2023-01-12",{"date":695,"type":23},"2030-09",{"name":697,"class":48},"Pirogov Russian National Research Medical University",{"id":699,"slug":700,"hasResults":12,"nctId":701,"briefTitle":702,"officialTitle":702,"acronym":703,"eligibilityCriteria":704,"healthyVolunteers":17,"sex":18,"minAge":172,"maxAge":58,"enrollmentInfo":705,"targetDuration":4,"studyType":24,"phases":707,"briefSummary":708,"conditions":709,"keywords":4,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":690,"lastUpdatePostDateStruct":715,"startDateStruct":716,"completionDateStruct":718,"leadSponsor":719,"locationsCount":49},"100442999","effect-of-hypoxic-conditioning-on-cerebrovascular-health-in-the-elderly-100442999","NCT05048680","Effect of Hypoxic Conditioning on Cerebrovascular Health in the Elderly","HYPOXAGE","Inclusion Criteria:\n\n* 60 to 80 years of age;\n* Being physically inactive (less than 150 min\u002Fweek of moderate to intense physical activity);\n* No chronic cardiovascular, respiratory, metabolic or neuromuscular disease counterindicating an exercise training or hypoxic conditioning program;\n* Health coverage;\n* Being able to provide written fully informed consent.\n\nExclusion Criteria:\n\n* Body-mass index \\>30 kg\u002Fm2;\n* Smoking (\\> cigarettes\u002Fday);\n* Alcohol use (\\> 10g\u002Fday);\n* Mental disorder or history of mental disorder;\n* Beta-blockade treatment;\n* Inability or refusal to provide informed consent;\n* No health coverage\n* People exceeding the annual ceiling of allowances received as a result of their participation in other clinical trials;\n* People deprived of freedom by judicial or administrative decision;\n* People subject to legal protection, who cannot be included in clinical trials.",{"count":706,"type":23},64,[26],"In line with the ever-growing aging of Western populations, the development of preventive strategies to slow down the effects of aging on cardiovascular health represents a major challenge in order to preserve functional capacities and a sufficient quality of life in the elderly. The alteration of vascular function (at the cerebral and systemic level) with aging is an important feature in the clinical picture including a decrease in physical and cognitive capacities. Although physical activity is recognized as an essential means of combating the effects of aging, optimizing its effects by defining the most effective strategies of practice remains a key objective. Offering alternative interventions to exercise training is also necessary for people who are unwilling or unable to engage in a physical activity program. In this context, hypoxic conditioning, alone or in conjunction with rehabilitative exercise training, is a new therapeutic modality with strong preclinical validity, in particular from a cardiovascular standpoint, and used in other pathologies to improve cardiovascular function and exercise performance and quality of life. Our aim is, therefore, to investigate the effect of hypoxic conditioning (alone or in conjunction with exercise training) on cerebrovascular health in the elderly.",[710,711,712,713,97,714,29],"Hypoxia","Cerebral Hypoxia","Brain Diseases","Exercise","Cognitive Decline",{"date":637,"type":41},{"date":717,"type":41},"2021-10-13",{"date":43,"type":23},{"name":720,"class":48},"University Hospital, Grenoble",{"id":722,"slug":723,"hasResults":12,"nctId":724,"briefTitle":725,"officialTitle":726,"acronym":4,"eligibilityCriteria":727,"healthyVolunteers":17,"sex":18,"minAge":115,"maxAge":314,"enrollmentInfo":728,"targetDuration":4,"studyType":24,"phases":730,"briefSummary":731,"conditions":732,"keywords":735,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":739,"lastUpdatePostDateStruct":740,"startDateStruct":741,"completionDateStruct":742,"leadSponsor":743,"locationsCount":49},"100628039","collagen-peptides-and-cellular-aging-100628039","NCT07456449","Collagen Peptides and Cellular Aging","Collagen Peptides and Cellular Aging: a Randomized, Placebo-controlled Intervention Study on Telomere Length, Inflammation, Body Composition, and Functional Capacity in Middle-aged and Older Adults","Inclusion Criteria:\n\n* Adults aged 50-70 years; both male and female participants are eligible\n* Body mass index (BMI) 25-30 kg\u002Fm²\n* Low to moderate physical activity: not meeting current WHO recommendations (\\\u003C150 minutes\u002Fweek) or ≤2 sessions\u002Fweek structured training\n* Able to live independently and mobile in daily life\n* No regular resistance training within the past 6 months\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Diagnosed chronic diseases relevant to the immune system, metabolism, or cellular aging (e.g., diabetes mellitus, cancer, cardiovascular, rheumatologic diseases)\n* Use of immunomodulatory, systemic anti-inflammatory, or hormonal medications (e.g., corticosteroids, immunosuppressants)\n* Acute infections or surgeries within the last 3 months\n* Regular use of supplements known to affect oxidative stress or cellular aging (e.g., high-dose antioxidants, CoQ10, omega-3 fatty acids, high-dose vitamin D)\n* Participation in another clinical study within the last 3 months\n* Vegetarian or vegan diet (product contains animal-derived collagen)",{"count":729,"type":23},125,[26],"The goal of this clinical trial is to learn if daily collagen peptide supplementation can stabilize or lengthen telomeres and improve related markers of cellular aging in adults aged 50-70 years with overweight and low-to-moderate physical activity (healthy volunteers without major chronic disease).\n\nMain questions it aims to answer are:\n\nDoes six months of collagen peptides stabilize or extend telomere length and increase telomerase activity compared with placebo? Are any telomere-related changes associated with lower inflammation, healthier body composition, and better functional health?\n\nResearchers will compare collagen as an intervention to a placebo group to see if collagen will influence aging markers.\n\nParticipants will take collagen peptides or a placebo daily for 24 weeks. They will attend three study visits: one before starting the intervention (T0), one at 3 months (T1), and one at 6 months (T2). At each visit, blood samples will be collected to measure telomere length, telomerase activity, and inflammation\u002Fredox markers. Participants will also undergo body composition assessments using bioelectrical impedance, complete functional tests of muscle strength and mobility, and fill out questionnaires on health and vitality.",[733,29,734],"Longevity","Biological Ageing",[97,736,377,737,472,738],"Collagen","Patient Care","Cellular aging","2026-04-28",{"date":661,"type":41},{"date":556,"type":41},{"date":137,"type":23},{"name":744,"class":48},"University of Vienna"]